Action DNA GENENTECH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Genentech, Inc.

Actions

DNA

US3687104063

Cours en clôture Nyse
Autres places de cotation
- USD - Graphique intraday de Genentech, Inc.
2016 Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie AW
2009 Genentech : Roche détient 93,2% du capital. CF

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
GENENTECH : Roche Completes Acquisition of Genentech
PR
GENENTECH : Roche Completes Tender Offer for Genentech
PR
GENENTECH : Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
PR
GENENTECH : Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
PR
GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
PR
Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
BU
Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox
BU
Genentech : Genentech Announces Second Quarter 2007 Results
BU
Genentech : Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
BU
Genentech : Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
BU
Genentech : Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
BU
Genentech : Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
BU
Genentech : Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
BU
Genentech : Genentech Announces June 4 Webcast Discussion of Data Presented at ASCO
BU
Genentech : Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
BU
Genentech : Genentech Extends Stock Repurchase Program
BU
Genentech : Genentech Announces First Quarter 2007 Results
BU
Genentech : Genentech to Provide Business Update at Annual Investment Community Meeting
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action DNA
  4. Actualités Genentech, Inc.
  5. Communiqués